Johnson & Johnson $JNJ Shares Acquired by Tsfg LLC

Tsfg LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 17.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,107 shares of the company’s stock after acquiring an additional 472 shares during the period. Tsfg LLC’s holdings in Johnson & Johnson were worth $475,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. GFG Capital LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson in the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.0%

Shares of NYSE JNJ opened at $189.02 on Monday. The company’s 50-day simple moving average is $183.28 and its 200-day simple moving average is $167.75. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The firm has a market cap of $455.40 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Stifel Nicolaus upped their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Finally, Sanford C. Bernstein raised their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.